Novan, Inc. (NASDAQ: NOVN) today announced that the Company has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”), a Japanese company with a prescription pharmaceutical business specializing in dermatology. Upon execution of the agreement, Sato will pay to Novan an initial payment of 1.25 billion JPY (approximately $11.0 million) for the exclusive rights to develop and commercialize in Japan Novan’s topical nitric oxide-releasing product candidate SB204 and ...
READ MORE
|
An international research team, led by Professor Peter Collignon from The Australian National University (ANU) Medical School, has found we need to take a much broader approach than simply focusing on antibiotic usage when it comes to fighting the spread of "superbugs". Superbugs or strains of bacteria that have adapted after coming into contact with antibiotics are a major global problem, causing increased deaths and suffering. The new research suggests there are steps we need to take...
AUSTRALIAN NATIONAL UNIVERSITY
READ MORE
|
Eli Lilly is leaning on oncology as a key pillar for growth going forward, but with news that its president of the business, Sue Mahony, is retiring, the drugmaker will need to find new leadership for the unit. During her 18 years at Lilly, Mahony has ascended the ranks—earning a spot on the executive committee—and helped see the drugmaker through some big changes. She managed the launch of breast cancer med Verzenio last year and the integration of ImClone, picked up in 2008 for $6....
FIERCEPHARMA
READ MORE
|
Portola Pharmaceuticals signed a $50-million loan agreement with Bristol-Myers Squibb Company (BMS) and Pfizer that provides additional funding toward development and clinical studies of AndexXa (andexanet alfa), an investigational compound that is a potential antidote for Factor Xa inhibitors. BMS and Pfizer will each loan Portola $25 million. The principal and interests will be repaid primarily through royalties on AndexXa commercial sales. Portola said in a statement the non-secured loan does...
WWW.PHARMTECH.COM
READ MORE
|
The Russian pharmaceutical market is expected resume its growth this year, both in volume and value terms, amid the ongoing recovery of the Russian economy from the financial....
READ MORE
|
“Pernicious” rebating and contracting schemes and “Kabuki drug-pricing constructs” expose consumers to high out-of-pocket costs for biosimilars and actively discourage competition from these more affordable alternatives, says FDA commissioner Scott Gottlieb. As part of FDA initiatives to reward innovation and promote patient access to medicines, the agency is working hard to support the development of high quality biosimilars and interchangeable products, he explained at ...
PHARMTECH
READ MORE
|